Perampanel + Placebo comparator
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Seizure Disorder Generalized Tonic Clonic
Conditions
Seizure Disorder Generalized Tonic Clonic
Trial Timeline
Sep 1, 2011 → Nov 1, 2015
NCT ID
NCT01393743About Perampanel + Placebo comparator
Perampanel + Placebo comparator is a phase 3 stage product being developed by Eisai for Seizure Disorder Generalized Tonic Clonic. The current trial status is completed. This product is registered under clinical trial identifier NCT01393743. Target conditions include Seizure Disorder Generalized Tonic Clonic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01393743 | Phase 3 | Completed |
Competing Products
20 competing products in Seizure Disorder Generalized Tonic Clonic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2007 | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 77 |
| perampanel | Eisai | Phase 2 | 52 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 77 |
| Perampanel + Placebo | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 77 |
| Adjunctive Zonisamide + Replacement with Zonisamide | Eisai | Approved | 85 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Eslicarbazepine Acetate tablets | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Approved | 85 |
| Perampanel + Perampanel | Eisai | Pre-clinical | 23 |